Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for treating hypertension and angina using salts of optically pure (-) amlodipine

a technology of optical purity and amlodipine, which is applied in the field of compound matter containing optical purity (-) amlodipine, can solve the problems of cardiovascular resistance and regional transmural pressure, chronic readjustment of cardiovascular hemodynamics, and decrease of both systolic and diastolic blood pressure when used as an antihypertensive agent, so as to avoid adverse effects and avoid adverse effects. , the effect of effectiv

Inactive Publication Date: 2001-10-11
SEPACOR INC
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, optical purity is important since certain isomers may actually be deleterious rather than simply inert.
Its ability to block, calcium channels in smooth muscle produces peripheral vasodilation resulting in decreases in both systolic and diastolic blood pressure.
As stated above, the racemic mixture of amlodipine produces peripheral vasodilation, resulting in decreases in both systolic and diastolic blood pressure when used as an antihypertensive agent.
Nevertheless, hypertension results in chronic readjustment of cardiovascular hemodynamics, alteration of blood vessel walls, cardiovascular resistance and regional transmural pressures.
However, treatment of hypertension does not always correspondingly benefit the morbidity and mortality of the condition, either because chronic hypertension has produced other significant and irreversible cardiovascular changes, or because present drugs have an adverse effect on some other risk factor for cardiovascular disease.
Cerebral ischemia, often the result of atherosclerotic disease or hypertension, results from insufficient cerebral circulation.
However, cerebral ischemia may result from either an intra- or extracranial interruption of arterial blood flow.
If the ischemia lasts for a somewhat more extended period, infarction results and the resulting neurologic damage is permanent.
In the absence of treatment, symptoms vary with individual arrhythmias, but are often the consequence of inadequate cardiac filling and output and often include fatigue, decreased exercise tolerance, syncope, shortness of breath, nausea, lightheadedness and the like.
Cardiac hypertrophy can result from excessive workload either due to an obstruction to outflow, termed systolic overload, or to excessive volumes presented to the heart in diastole, termed diastolic overload.
Systolic overload results in concentric ventricular hypertrophy, in which there is an increased thickness in the walls of the heart not associated with increased volume.
An inadequate cardiac output results from the heart's failure in systolic or diastolic overload, leading to fatigue, shortness of breath, pulmonary congestion, edema and the like.
In an electrically unstable heart, diverse neural impulses to the heart may provoke coronary vascular spasm.
This may result in enhanced myocardial ischemia and arrhythmia, which in turn may culminate in ventricular fibrillation and sudden cardiac death.
The pain, which can be severe aching or pressure, leads to apprehension.
Congestive failure results in poor cardiac output and elevated left-ventricular diastolic pressure, leading to dyspnea, fatigue, peripheral edema, and coughing.
Classic migraine typically begins with visual auras followed by severe headaches, often accompanied by nausea and vomiting.
The most common cause of intrinsic renal failure is prolonged renal ischemia.
It is a structurally caused permanent or progressive decline in several dimensions of intellectual function that interferes substantially with individual normal social or economic activity.
The most common clinical picture is slow disintegration of personality and intellect due to impaired insight and judgment and loss of affect.
Memory impairment increases, beginning with problems recalling recent events or finding names.
Many calcium channel antagonists cause significant adverse effects.
In contrast to the situation with several other calcium channel antagonists, however, the racemic mixture of amlodipine has not been found to cause either marked or prolonged direct effects on heart rate or the reflex consequence of vasodilation.
However, the administration of the racemic mixture of amlodipine to a human has been found to cause still other adverse effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating hypertension and angina using salts of optically pure (-) amlodipine

Examples

Experimental program
Comparison scheme
Effect test

example 1

4.1. Example 1

Vascular Selectivity Studies

[0063] The relative potency of optically pure (-) amlodipine and racemic amlodipine as calcium channel antagonists and negative inotropic agents are determined by a pharmacological study. Evaluation of these compounds and others in in vitro test systems provide results, from which the vascular selectivity of a particular compound can be assessed. Calcium channel antagonist activity of the compounds as a function of their molar concentration can be evaluated by measuring their inhibition of the calcium-induced contraction of strips of rat aorta immersed in a bath of Krebs-Henseleit buffer containing 45 mM K.sup.+ and no Ca.sup.2+. In the presence of various concentrations of the antagonists, inhibition would occur in the contraction of this isolated tissue preparation in response to the addition of calcium chloride. Antagonists may be compared by examining the molar concentration of compounds inhibiting the calcium-induced contraction by 50%....

example 2

4.2. Example 2

Radioligand Binding Studies

[0065] Hind limb skeletal muscles from rats or guinea pigs are minced and homogenized. After filtration and repeated centrifugation, the pellet is homogenized and diluted in a Tris buffer to a protein concentration of 1-3 mg / ml. Volumes of this suspension containing 3-10 .mu.g protein are incubated in the presence of a fixed concentration of 0.2 to 0.5 nM (+)-[.sup.3H]-isradipine or a similar radioactive ligand and increasing concentrations of racemic amlodipine, (-) amlodipine or (+) amlodipine. After 1 hour incubation, the bound and free radioactivity is measured in a scintillation counter and the affinity of the test compounds to the receptors is calculated.

example 3

4.3. Example 3

Effects on Coronary Vascular Resistance in the Guinea Pig Langendorff Heart Preparation

[0066] Male guinea pigs weighing between 400 and 450 g are killed by cervical dislocation. The hearts are removed and perfused with Krebs-Henseleit solution at constant pressure (60 cm water) by means of retrograde cannulation of the aorta in a Langendorff apparatus. The Krebs-Henseleit solution, consisting of 118.0 mM NaCl, 4.7 mM KCl, 5.5 mM CaCl.sub.2, 1.2 nM MgSO.sub.4, 25.0 mM NaHCO.sub.3 and 5.0 mM glucose, is prewarmed to 37.degree. C. and gassed with a mixture of 95% oxygen / 5% carbon dioxide. A balloon catheter connected to a pressure transducer is placed in the left ventricle via the left atrium and is preloaded to a pressure of 40 mm Hg. Coronary perfusate flow is measured continuously, and changes in heart rate and left ventricular contractility are also monitored continuously.

[0067] Each experiment consists of a 30 minute equilibrium period during which coronary flow is s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molar concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
pressureaaaaaaaaaa
Login to View More

Abstract

Methods and compositions are disclosed utilizing the optically pure (-) isomer of amlodipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of amlodipine. The (-) isomer of amlodipine is also useful for the treatment of angina and such other conditions as may be related to the activity of (-) amlodipine as a calcium channel antagonist such as cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure, without the concomitant liability of adverse effects associated with the racemic mixture of amlodipine.

Description

1. BACKGROUND OF THE INVENTION[0001] This invention relates to novel compositions of matter containing optically pure (-) amlodipine. These compositions possess potent activity in treating both systolic and diastolic hypertension while avoiding adverse effects including but not limited to edema of the extremities, headache and dizziness, which are associated with administration of the racemic mixture of amlodipine. Additionally, these novel compositions of matter containing optically pure (-) amlodipine are useful in treating angina and such other conditions as may be related to the activity of (-) amlodipine as a calcium channel antagonist including but not limited to cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure--while avoiding the adverse effects associated with administration of the racemic mixture of amlodipine. Also disclosed are methods for treating the above-describ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/44A61P9/00A61P9/12
CPCA61K31/44Y10S514/866Y10S514/929A61P9/00A61P9/12
Inventor YOUNG, JAMES W.
Owner SEPACOR INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products